COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC: https://www.coronavirus.gov
Get the latest research information from NIH: https://www.nih.gov/coronavirus

Coronavirus Guidance for NIH Applicants and Grantees: https://grants.nih.gov/grants/natural_disasters/corona-virus.htm

Dr. Anita Szajek

Dr. Anita Szajek

Scientific Review Officer



Biography

Division:
Division of Basic and Integrative Biological Sciences DBIB
IRG:
Biological Chemistry and Macromolecular Biophysics BCMB
Study Section:
Synthetic and Biological Chemistry A SBCA

Dr. Anita Szajek received her Ph.D. in bioinorganic chemistry from University of Wisconsin in Madison, and she did postdoctoral work at Parke-Davis Pharmaceuticals and NIH National Cancer Institute on matrix metalloproteinases. She then joined Emergent BioSolutions as a scientist working to develop diagnostics, vaccines and pharmaceuticals for chronic bacterial infections and infectious diseases. She subsequently joined Human Genome Sciences as a senior scientist focused on purification process development activities, scale-up and analytical assay development from preclinical to Phase III. Dr. Szajek next moved to United States Pharmacopeia, where she served as a principal scientific liaison for over 10 years. She worked closely with FDA and WHO to develop public standards for heparins, blood products, proteins and synthetic peptides.